The biology of VEGF and its receptors
The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated in pathological angiogenesis associated with tumors, intraocular neovascular disorders and other conditions. The biological effects of VEGF are mediated by two receptor tyrosine kinases (RTKs), VEGFR-1 and VEGFR-2, which differ considerably in signaling properties. Non-signaling co-receptors also modulate VEGF RTK signaling. Currently, several VEGF inhibitors are undergoing clinical testing in several malignancies. VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is well established that the formation of blood vessels occurs by angiogenesis and that vascular endothelial growth factor (VEGF) is a key molecule in promoting angiogenesis (Ferrara et al., 2003).”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Ferrara et al., 2003
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 1×
“VEGF induces a potent angiogenic response in a variety of in vivo model”
BackgroundSelf-citationThe Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Self-citationMechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972 · cited 1×
“VEGF is known also as vascular permeability factor, based on its ability to induce vascular leakag”
BackgroundFailure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Self-citationVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“Many molecules have been implicated as positive regulators of angiogenesis, including acidic fibroblast growth factor (FGF), basic FGF, transforming growth factor (TGF)-α, TGF-β, hepatocyte growth factor (HGF, or scatter factor), tumor necrosis factor-α, angiogenin, interleukin (IL)-8 and the angiopoietin”
Background
Research works printed but not linked: 3
- Presta, L.G. et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
- Yang, J.C. et al. A randomized trial of bevacizumab (anti-VEGF antibody) in metastatic renal cancer. N. Engl. J. Med. (in the press).
Cited by
Items 1,001–1,056 of 1,056
Zhou, J., Cai, B., Jang, Y. P., Pachydaki, S., Schmidt, A. M., & Sparrow, J. R. (2005) · Experimental Eye Research · doi:10.1016/j.exer.2004.11.009 · Cited by 113
Bujold, E., Romero, R., Chaiworapongsa, T., KIM, Y. M., Kim, G. J., Kim, M. R., Espinoza, J., Gonçalves, L. F., Edwin, S., & Mazor, M. (2005) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050500202493 · Cited by 110
“This isoform binds VEGF or PlGF and inhibits their biological activities [40,41,43].”
BackgroundInfluentialVEGF-targeted cancer therapeutics—paradoxical effects in endocrine organs
Cao, Y. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.114 · Cited by 109
Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease
Wada, K., Arai, H., Takanashi, M., Fukae, J., Oizumi, H., Yasuda, T., Mizuno, Y., & Mochizuki, H. (2006) · NeuroReport · doi:10.1097/01.wnr.0000215769.71657.65 · Cited by 109
“action of VEGF [12], such increased expression levels could induce different reactions in different cases.”
BackgroundChen, Q., Xu, L., Chen, J., Yang, Z., Liang, C., Yang, Y., & Liu, Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.021 · Cited by 104
Light Triggered Oxygen-Affording Engines for Repeated Hypoxia-Resistant Photodynamic Therapy
Zhou, T.-J., Xing, L., Fan, Y.-T., Cui, P.-F., & Jiang, H.-L. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.016 · Cited by 104
Zaytseva, Y. Y., Elliott, V. A., Rychahou, P., Mustain, W. C., Kim, J. T., Valentino, J., Gao, T., O’Connor, K. L., Neltner, J. M., Lee, E. Y., et al. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu042 · Cited by 104
“Induction of vascular endothelial growth factor-A (VEGF-A) is a critical step in tumor angiogenesis (13).”
BackgroundVascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity
Kitagawa, Y., Dai, J., Zhang, J., Keller, J. M., Nor, J., Yao, Z., & Keller, E. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1809 · Cited by 101
“Vascular endothelial growth factor (VEGF) is a key regulator of physiologic and pathophysiologic angiogenesis (14).”
BackgroundHossein Pourgholami, M., Yan Cai, Z., Lu, Y., Wang, L., & Lawson Morris, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1181 · Cited by 100
Disruption of the Rb-Raf-1 Interaction Inhibits Tumor Growth and Angiogenesis
Dasgupta, P., Sun, J., Wang, S., Fusaro, G., Betts, V., Padmanabhan, J., Sebti, S. M., & Chellappan, S. P. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9527-9541.2004 · Cited by 98
“Raf-1 function is known to be important for neovascularization induced by proangiogenic mediators such as bFGF and VEGF ( 22 ).”
BackgroundInfluentialCardiotoxicity of Anticancer Therapeutics
Dong, J., & Chen, H. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00009 · Cited by 95
“Mechanistically, VEGF binds to three receptor sites—VEGFR-1 (Flt-1), VEGFR-2 (Flk-1), and VEGFR-3 (24).”
BackgroundHe, Z., Opland, D. M., Way, K. J., Ueki, K., Bodyak, N., Kang, P. M., Izumo, S., Kulkarni, R. N., Wang, B., Liao, R., et al. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000209500.15801.4e · Cited by 94
Pepe, M., Mamdani, M., Zentilin, L., Csiszar, A., Qanud, K., Zacchigna, S., Ungvari, Z., Puligadda, U., Moimas, S., Xu, X., et al. (2010) · Circulation Research · doi:10.1161/circresaha.110.220855 · Cited by 93
Holekamp, N. M., Liu, Y., Yeh, W.-S., Chia, Y., Kiss, S., Almony, A., & Kowalski, J. W. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.12.018 · Cited by 88
“Other reasons for the low levels of anti-VEGF utilization may include concerns about the localized and systemic side effects of frequent anti-VEGF treatment, including endophthalmitis, retinal detachment, and myocardial infarction or stroke,28–31 although a recent 4-year longitudinal study of ranibizumab patients foun…”
BackgroundInfluentialCurrent targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
Neurotrophic factors in Parkinson’s disease are regulated by exercise: Evidence-based practice
da Silva, P. G. C., Domingues, D. D., de Carvalho, L. A., Allodi, S., & Correa, C. L. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.02.017 · Cited by 87
“Its function is associated with promotion of vasculogenesis and angiogenesis, restoring oxygen support in regions where blood flow is inadequate [87–89].”
BackgroundKalayoglu, M. V., Bula, D., Arroyo, J., Gragoudas, E. S., D’Amico, D., & Miller, J. W. (2005) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-005-1169-y · Cited by 86
“Vascular endothelial growth factor (VEGF), a key regulator of physiological angiogenesis [11], is one such cytokine central to the development of neovascular AMD.”
Kyosseva, S. V., Chen, L., Seal, S., & McGinnis, J. F. (2013) · Experimental Eye Research · doi:10.1016/j.exer.2013.08.003 · Cited by 82
“VEGFs are the most important regulators of angiogenesis (Ferrara et al., 2003).”
BackgroundTreg cell therapy: How cell heterogeneity can make the difference
Giganti, G., Atif, M., Mohseni, Y., Mastronicola, D., Grageda, N., Povoleri, G. A., Miyara, M., & Scottà, C. (2021) · European Journal of Immunology · doi:10.1002/eji.201948131 · Cited by 82
Lueck, K., Wasmuth, S., Williams, J., Hughes, T. R., Morgan, B. P., Lommatzsch, A., Greenwood, J., Moss, S. E., & Pauleikhoff, D. (2011) · Eye · doi:10.1038/eye.2011.109 · Cited by 80
VEGF and RANKL Regulation of NFATc1 in Heart Valve Development
Combs, M. D., & Yutzey, K. E. (2009) · Circulation Research · doi:10.1161/circresaha.109.196469 · Cited by 76
Tuning the surface potential to reprogram immune microenvironment for bone regeneration
Li, M., Chu, X., Wang, D., Jian, L., Liu, L., Yao, M., Zhang, D., Zheng, Y., Liu, X., Zhang, Y., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121408 · Cited by 72
Sapra, P., Kraft, P., Pastorino, F., Ribatti, D., Dumble, M., Mehlig, M., Wang, M., Ponzoni, M., Greenberger, L. M., & Horak, I. D. (2011) · Angiogenesis · doi:10.1007/s10456-011-9209-1 · Cited by 70
“, in which daily, but not intermittent, administration of topotecan, another topoisomerase I inhibitor, resulted in a sustained tumor growth inhibition [7].”
BackgroundFibroblast-associated tumour microenvironment induces vascular structure-networked tumouroid
Lee, S. W., Kwak, H. S., Kang, M.-H., Park, Y.-Y., & Jeong, G. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-20886-0 · Cited by 68
Wang, L., Feng, Y., Xie, X., Wu, H., Su, X. N., Qi, J., Xin, W., Gao, L., Zhang, Y., Shah, V. H., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.04.050 · Cited by 66
“It is well known that vascular growth factors (VEGFs) play an important role in the regulation of angiogenesis via the receptors VEGFRs and NRPs [4].”
BackgroundGene therapy for age-related macular degeneration
Moore, N. A., Bracha, P., Hussain, R. M., Morral, N., & Ciulla, T. A. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1356817 · Cited by 63
“There are seven different members of the VEGF family including VEGF-A, PlGF (placental growth factor), VEGF-B, VEGF-C, VEGF-D, VEGF-E, and snake venom VEGF.”
BackgroundInfluentialCombination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models
Mariniello, B., Rosato, A., Zuccolotto, G., Rubin, B., Cicala, M. V., Finco, I., Iacobone, M., Frigo, A. C., Fassina, A., Pezzani, R., et al. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0337 · Cited by 63
“Following the binding to VEGF receptor 2 (VEGFR2), VEGF mediates its effects on proliferation, survival, adhesion, migration, and gene expression in endothelial cells (Ferrara et al. 2003).”
BackgroundInfluentialBrain homeostasis: VEGF receptor 1 and 2—two unequal brothers in mind
Wittko-Schneider, I. M., Schneider, F. T., & Plate, K. H. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1279-3 · Cited by 62
“VEGF-A is a mitogen for endothelial cells and a survival-promoting factor for newly formed vessels that is indispensible for the development of the vascular system [25].”
BackgroundVascular Tissue Engineering: Effects of Integrating Collagen into a PCL Based Nanofiber Material
Bertram, U., Steiner, D., Poppitz, B., Dippold, D., Köhn, K., Beier, J. P., Detsch, R., Boccaccini, A. R., Schubert, D. W., Horch, R. E., et al. (2017) · BioMed Research International · doi:10.1155/2017/9616939 · Cited by 62
“Vascular endothelial growth factor (VEGF) is one key regulator of angiogenesis [37].”
BackgroundLamartina, S., Cimino, M., Roscilli, G., Dammassa, E., Lazzaro, D., Rota, R., Ciliberto, G., & Toniatti, C. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1083 · Cited by 59
“A vast amount of pre-clinical and clinical data indicate that misregulated expression of vascular endothelial growth factor (VEGF), a potent pro-angiogenic and permeability enhancing factor produced by several different ocular cell types and up-regulated in response to hypoxic conditions, is a key pathogenetic event […”
BackgroundJo, D. H., Koo, T., Cho, C. S., Kim, J. H., Kim, J.-S., & Kim, J. H. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.009 · Cited by 57
“In particular, HIF-1a is upregulated in pathological states associated with various retinal vascular diseases, including AMD and diabetic retinopathy; a key effect is that HIF-1a promotes the expression of VEGF-A, one of the most potent players in pathological angiogenesis.(15,17,18) Because there are several HIF-1a-i…”
BackgroundDing, C., Li, L., Yang, T., Fan, X., & Wu, G. (2016) · BMC Cancer · doi:10.1186/s12885-016-2834-8 · Cited by 56
Zhang, Y., Xiong, X., Huai, Y., Dey, A., Hossen, M. N., Roy, R. V., Elechalawar, C. K., Rao, G., Bhattacharya, R., & Mukherjee, P. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00262 · Cited by 53
Boudria, A., Abou Faycal, C., Jia, T., Gout, S., Keramidas, M., Didier, C., Lemaître, N., Manet, S., Coll, J.-L., Toffart, A.-C., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0486-7 · Cited by 53
Bocci, G., Danesi, R., Marangoni, G., Fioravanti, A., Boggi, U., Esposito, I., Fasciani, A., Boschi, E., Campani, D., Bevilacqua, G., et al. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.062 · Cited by 49
Ozbudak, I. H., Karaveli, S., Simsek, T., Erdogan, G., & Pestereli, E. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.11.028 · Cited by 46
“Several clinicopathologic studies have shown a direct association between VEGF expression and increased microvascular density (MVD) demonstrating intratumoral angiogenesis [4,5].”
BackgroundClinical trials with anti‐angiogenic agents in hematological malignancies
Medinger, M., & Mross, K. (2010) · Journal of Angiogenesis Research · doi:10.1186/2040-2384-2-10 · Cited by 40
“Thus, VEGF and VEGFR represent significant anti-cancer therapy targets, which elegantly bypass potential tumor-related treatment barriers [4].”
InfluentialElectroconvulsive seizures stimulate the vegf pathway via mTORC1
Elfving, B., & Wegener, G. (2012) · Synapse · doi:10.1002/syn.21518 · Cited by 40
“In addition to these receptors, VEGF could interact with a family of coreceptors, neuropilin (NRP) 1 and 2 (Ferrara et al., 2003).”
BackgroundAnti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
Ria, R., Melaccio, A., Racanelli, V., & Vacca, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061765 · Cited by 40
“Ferrara and Henzel first purified VEGF, a glycoprotein with mitogenic activity for vascular ECs, from bovine pituitary folliculo-stellate cells [62,63].”
BackgroundBosquiazzo, V. L., Ramos, J. G., Varayoud, J., Muñoz-de-Toro, M., & Luque, E. H. (2007) · Reproduction · doi:10.1530/rep-06-0168 · Cited by 35
Fujita, D., Tanabe, A., Sekijima, T., Soen, H., Narahara, K., Yamashita, Y., Terai, Y., Kamegai, H., & Ohmichi, M. (2010) · Journal of Endocrinology · doi:10.1677/joe-10-0027 · Cited by 33
“VEGF has been implicated as playing an important role in placental angiogenesis (Ferrara et al .”
BackgroundShi, Z., Chen, Y., Lu, C., Dong, L.-M., Lv, J.-W., Tuo, Q.-H., Qin, L., Cheng, S.-W., Bu, L.-L., Lin, N., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.002 · Cited by 32
Vascular endothelial cell activation by adult Dirofilaria immitis antigens
Morchón, R., Rodríguez-Barbero, A., Velasco, S., López-Belmonte, J., & Simón, F. (2008) · Parasitology International · doi:10.1016/j.parint.2008.05.004 · Cited by 27
“This eicosanoid is implicated in the regulation of vascular function, wound repair, inflammatory processes and lung injury [20,21], while NO has been implicated in differentmechanisms, including the autocrine regulation of the vascular pressure [22].”
BackgroundPolymeric micelles for siRNA delivery
Falamarzian, A., Xiong, X.-B., Uludag, H., & Lavasanifar, A. (2012) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(12)50004-3 · Cited by 25
Emons, J., Chagin, A. S., Malmlöf, T., Lekman, M., Tivesten, Å., Ohlsson, C., Wit, J. M., Karperien, M., & Sävendahl, L. (2010) · Journal of Endocrinology · doi:10.1677/joe-09-0337 · Cited by 25
“…FLT1) and VEGFR-2 (also known as kinase insert domain-containing receptor, KDR), with almost all responses being mediated through the second receptor, which has also been detected at the chondro-osseous junction in the mouse growth plate (Gerber et al. 1999, Ferrara et al. 2003, Dai & Rabie 2007).”
Schulte, B., Mohindra, N., Milhem, M., Attia, S., Robinson, S., Monga, V., Hirbe, A. C., Oppelt, P., Charlson, J., Helenowski, I., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01448-0 · Cited by 19
“The VEGF pathway may be inhibited by tyrosine kinase inhibitors (TKIs), such as pazopanib.(9) In 2012, the FDA approved the TKI, pazopanib, in advanced and metastatic non-adipocytic STS previously treated with chemotherapy based on the phase III randomised, double-blind, placebo-controlled PALETTE study.”
BackgroundReducing VEGFB expression regulates the balance of glucose and lipid metabolism in mice via VEGFR1
Luo, X., Li, R.-R., Li, Y.-Q., Yu, H.-P., Yu, H.-N., Jiang, W.-G., & Li, Y.-N. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12801 · Cited by 19
Miyokawa-Gorin, K., Takahashi, K., Handa, K., Kitahara, A., Sumitani, Y., Katsuta, H., Tanaka, T., Nishida, S., Yoshimoto, K., Ohno, H., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.01.145 · Cited by 18
Effects of trauma, hemorrhagic shock, and chronic stress on lung vascular endothelial growth factor
Loftus, T. J., Thomson, A. J., Kannan, K. B., Alamo, I. G., Ramos, H. N., Whitley, E. E., Efron, P. A., & Mohr, A. M. (2017) · Journal of Surgical Research · doi:10.1016/j.jss.2016.10.023 · Cited by 17
Orth, M., Fritz, T., Stutz, J., Scheuer, C., Ganse, B., Bullinger, Y., Lee, J. S., Murphy, W. L., Laschke, M. W., Menger, M. D., et al. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.809397 · Cited by 15
“VEGF is a well-known key regulator of physiological angiogenesis during embryogenesis and skeletal growth (Ferrara et al., 2003), whereas BMP-2 promotes differentiation of mesenchymal stem cells and osteoprogenitor cells into osteoblasts and thereby acts osteogenic (Cheng et al.”
BackgroundChen, Q., Chen, Z., Li, F., Zha, H., He, W., Jiang, F., Wei, J., Xu, J., Li, R., Cai, L., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115456 · Cited by 14
Wang, N., Zhu, S., Chen, S., Zou, J., Zeng, P., & Tan, S. (2025) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0147 · Cited by 12
Protein kinase D activity controls endothelial nitric oxide synthesis
Aicart-Ramos, C., Sánchez-Ruiloba, L., Gómez-Parrizas, M., Zaragoza, C., Iglesias, T., & Rodríguez-Crespo, I. (2014) · Journal of Cell Science · doi:10.1242/jcs.148601 · Cited by 12
“VEGF is mainly secreted from mesenchymal, stromal and epithelial sources to act on endothelial cells in both arteries and veins, and its receptors are transmembrane proteins that belong to the receptor tyrosine kinase family (Ferrara et al., 2003; Ho and Kuo, 2007; Olsson et al., 2006).”
Update on Anti-Angiogenesis Therapy in Colorectal Cancer
Ciombor, K. K., & Goldberg, R. M. (2015) · Current Colorectal Cancer Reports · doi:10.1007/s11888-015-0292-3 · Cited by 11
An Investigation of Vascular Endothelial Growth Factor (VEGFR-1 and VEGFR-2) in Burn Wound Healing.
(2022) · PubMed Central · doi:10.22092/ari.2022.356981.1954 · Cited by 8
AAV2.7m8-Mediated MicroRNA Expression Suppresses VEGF-Induced Angiogenic Responses in HUVEC
Yang, J. Y., Choi, J.-S., & Park, T. K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073123 · Cited by 1
“In the present study, VEGF-A165—the predominant and most bioactive isoform of VEGF—was employed to elicit angiogenic signaling in endothelial cells, given its well-documented role in activating VEGFR2-dependent MAPK signaling cascades [12,44].”
Metadata
- Authors
- Ferrara, N., Gerber, H.-P., & LeCouter, J.
- Affiliations
- Genentech (US)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature Medicine
- Published
- 2003-06-01
- Volume
- 9
- Issue
- 6
- Pages
- 669-676
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2000292756
- Cited by
- 9,591
- References
- 144
- Citations by year
- 2026: 154 · 2025: 270 · 2024: 292 · 2023: 317 · 2022: 336 · 2021: 386 · 2020: 379 · 2019: 403 · 2018: 384 · 2017: 466 · 2016: 460 · 2015: 485 · 2014: 551 · 2013: 527 · 2012: 580
- FWCI
- 28.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- vascular endothelial growth factor, VEGF receptors, VEGFR1, VEGFR2, receptor tyrosine kinase signaling, angiogenesis, pathological angiogenesis, tumor angiogenesis, intraocular neovascularization, VEGF inhibitors, age-related macular degeneration, vascular leakage, embryonic development
- MeSH terms
- Animals, Clinical Trials as Topic, Endothelium, Vascular, Growth Substances, Humans, Lymphokines, Neovascularization, Pathologic, Oxygen, Signal Transduction, Endothelial Growth Factors, Neovascularization, Physiologic, Protein Isoforms, Intercellular Signaling Peptides and Proteins, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.